Chronic Lymphocytic LeukemiaPhase 2NCT06588478
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase 2 study testing Pirtobrutinib in people with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, run by Loxo Oncology, Inc. at 129 sites in 18 countries.
Trial summary
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- What is being tested?
- Pirtobrutinib
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 249 participants
- Where
- 129 sitesin 18 countries
- Study dates
- 3 Jan 2025to Dec 2028
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Have confirmed diagnosis of CLL/SLL as defined by iwCLL 2018 criteria.
- Part 1: Have received prior CLL/SLL treatment
- Have received at least 1, but not more than 3 lines of prior treatment for CLL/SLL
- Have received a covalent BTK inhibitor
- Part 2: Have received no prior treatment for CLL/SLL
- Part 1 - Known 17p deletion status (positive or negative)
Show all 10Show fewer
- Part 2 - Must have 17p deletion (positive)
- Have a requirement for therapy consistent with iwCLL 2018 criteria for initiation of therapy
- Capable of swallowing oral study medication.
- Have an Eastern Cooperative Oncology Group Performance Status (ECOG) score of 0 to 2.
Who cannot join
- Have received prior treatment with a BTK degrader or a noncovalent BTK inhibitor
- Have a history of greater than or equal to (>=) Grade 3 bleeding due to treatment with a BTK inhibitor
- Have known or suspected Richter's transformation
- Have known or suspected history of central nervous system involvement by CLL/SLL
- Previous or concurrent cancer distinct from CLL/SLL within 3 years before randomization. Exceptions may occur with documented sponsor approval. Examples include:
- nonmelanoma skin cancer or lentigo malignant melanoma
Show all 9Show fewer
- cervical carcinoma in situ
- localized prostate cancer undergoing active surveillance, and
- localized (for example, lymph node negative) breast cancer with no evidence of active disease present for more than 3 years. Individual may be receiving adjuvant hormonal therapy
Trial locations and contacts
129 sites in 18 countries. Contact the study team or a site near you to ask about taking part.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or contact
Physicians interested in becoming principal investigators please contact contact
129 sites in 18 countries
United States20 sites, 20 recruiting
- Recruiting
Rocky Mountain Cancer Center
Aurora, Colorado, 80012
303-418-7639
John Burke
- Recruiting
USO-Texas Oncology-Central/South Texas
Austin, Texas, 78705
512-421-4100
Jason Melear
- Recruiting
American Oncology Partners, PA
Bethesda, Maryland, 20817
301-571-2016
Victor Priego
- Recruiting
Boston Medical Center
Boston, Massachusetts, 02118
Andrew Wilks
- Recruiting
Ironwood Cancer & Research Centers
Chandler, Arizona, 85224
Michael Musci
- Recruiting
City of Hope National Medical Center
Duarte, California, 91010
800-826-4673
Alexey Danilov
- Recruiting
Saint Elizabeth Medical Center Edgewood
Edgewood, Kentucky, 41017
Miguel Islas-Ohlmayer
- Recruiting
Williamette Valley Cancer Institute & Research Center
Eugene, Oregon, 97401
541-683-5001
Jeff Sharman
- Recruiting
East Carolina University
Greenville, North Carolina, 27834
252-744-1015
Darla Liles
- Recruiting
Gulfport Memorial Hospital
Gulfport, Mississippi, 39501
228-575-1234
Pamela Tuli
- Recruiting
USO-Virginia Oncology Associates
Hampton, Virginia, 23666
757-368-0437
Celesteann Bremer
- Recruiting
Comprehensive Cancer Centers of Nevada
Henderson, Nevada, 89074
Anthony Nguyen
- Recruiting
City of Hope National Medical Center
Irvine, California, 92618
626-218-2405
Alexey Danilov
- Recruiting
University of Miami Hospital and Clinics, Sylvester Cancer Center
Miami, Florida, 33136
Alvaro Alencar
- Recruiting
City of Hope National Medical Center, Atlanta Cancer Center
Newnan, Georgia, 30265
Sabarish Ayyappan
- Recruiting
Palo Alto Medical Foundation Research Institute (PAMFRI)
Palo Alto, California, 94304
Roozbeh Mohajer
- Recruiting
Stanford Cancer Center
Palo Alto, California, 94304
Bita Fakhri
- Recruiting
Sarah Cannon Research Institute/SCRI
The Woodlands, Texas, 77380
999-999-9999
SMO Sarah Cannon Research Inst.
- Recruiting
Mission Cancer + Blood
Waukee, Iowa, 50263
515-282-2921
Tara Graff
- Recruiting
Cancer Care Associates Of York
York, Pennsylvania, 17403
717-741-9229
Jackson Gao
Spain14 sites, 14 recruiting
- Recruiting
Hospital Universitari Vall d'Hebron
Barcelona, 08035
+34 93 274 61 00 EXT 3806
Francisco Bosch Albareda
- Recruiting
Hospital Clínic de Barcelona
Barcelona, 08036
932275400
Pablo Mozas
- Recruiting
Institut Català d'Oncologia - L'Hospitalet
L'Hospitalet Del Llobregat, 08908
Ana Oliveira Ramos
- Recruiting
Clinica Universidad de Navarra
Madrid, 28027
Carlos Grande Garcia
- Recruiting
Hospital Universitario Infanta Leonor
Madrid, 28031
911918932
Jose Angel Hernandez Rivas
- Recruiting
MD Anderson Cancer Center
Madrid, 28033
Adolfo de la Fuente Burguera
- Recruiting
Hospital Universitario Ramón y Cajal
Madrid, 28034
34913368637
Javier Lopez Jimenez
- Recruiting
Hospital Universitario Puerta de Hierro Majadahonda
Majadahonda, 28222
91 191 69 71
JOSE GARCIA VELA
- Recruiting
Hospital Costa del Sol
Marbella, 29603
+34951976957
ANGELES MEDINA PEREZ
- Recruiting
Hospital Universitario Central de Asturias
Oviedo, 33011
985108000
Angel Ramirez Payer
- Recruiting
Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca
Salamanca, 37007
34923291100
Almudena Navarro Bailon
- Recruiting
Hospital Universitario Marqués de Valdecilla
Santander, 39008
34942315321
LUCRECIA YANEZ SAN SEGUNDO
- Recruiting
Hospital Universitario Virgen Macarena
Seville, 41009
3495049697
Alicia Rodriguez Fernandez
- Recruiting
Hospital Universitario Virgen Del Rocio
Seville, 41013
34 955013277
Fatima de la Cruz Vicente
Australia10 sites, 10 recruiting
- Recruiting
Flinders Medical Centre
Adelaide, 5042
Kate Manos
- Recruiting
Bankstown-Lidcombe Hospital
Bankstown, 2200
Adrian Yeung
- Recruiting
Box Hill Hospital
Box Hill, 3128
Ahmad Zargari
- Recruiting
Coffs Harbour Health Campus
Coffs Harbour, 2450
Kyle Crassini
- Recruiting
Royal Hobart Hospital
Hobart, 7000
61 3 6166 6655
Rosemary Harrup
- Recruiting
ICON Cancer Centre - Kurralta Park
Kurralta Park, 5037
Ka Chun Cheung
- Recruiting
Latrobe Regional Health
Traralgon, 3844
Michael Ashby
- Recruiting
Calvary Mater Newcastle
Waratah, 2298
0240143021
Alex Holmes
- Recruiting
The Perth Blood Institute - West Perth
West Perth, 6005
Ross Baker
- Recruiting
Princess Alexandra Hospital
Woolloongabba, 4102
Sasanka Handunnetti
Italy10 sites, 10 recruiting
- Recruiting
A.O.U.C. Policlinico di Bari
Bari, 70124
Francesco Albano
- Recruiting
Azienda Ospedaliero Universitaria S.Anna
Cona, 44124
+390532236977
Antonio Cuneo
- Recruiting
Azienda Ospedaliera Universitaria Careggi
Florence, 50134
00390557947958
alessandro sanna
- Recruiting
ASST Grande Ospedale Metropolitano Niguarda
Milan, 20162
Anna Maria Frustaci
- Recruiting
Azienda Ospedaliero Universitaria Maggiore della Carità
Novara, 28100
+39 03213733880
Riccardo Moia
- Recruiting
Azienda Ospedale - Università Padova
Padova, 35128
0498217809
Andrea Visentin
- Recruiting
Az. Osp. Ospedali Riuniti VILLA SOFIA-CERVELLO
Palermo, 90146
+390916802773
CATERINA PATTI
- Recruiting
AO Santa Maria della Misericordia
Perugia, 06132
+390755783990
PAOLO SPORTOLETTI
- Recruiting
AOU Policlinico Umberto I
Roma, 00161
0649974773
Maurizio Martelli
- Recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore
Roma, 00168
+39 0630157833
LUCA LAURENTI
Belgium9 sites, 9 recruiting
- Recruiting
Institut Jules Bordet
Anderlecht, 1070
Virginie De Wilde
- Recruiting
AZ Sint-Jan Brugge-Oostende AV
Bruges, 8000
3250452320
Sylvia Snauwaert
- Recruiting
UZ Gent
Ghent, 9000
+32 9 332 21 25
Fritz Offner
- Recruiting
Groupe Jolimont
La Louvière, 7100
VANESSA DELRIEU
- Recruiting
UZ Leuven
Leuven, 3000
Ann Janssens
- Recruiting
Clinique Saint Pierre
Ottignies, 1340
Thierry Connerotte
- Recruiting
AZ Delta vzw
Roeselare, 8800
003251237322
Lien Deleu
- Recruiting
AZ Nikolaas
Sint-Niklaas, B-9100
Vanessa Van Hende
- Recruiting
CHR Verviers - La Tourelle
Verviers, 4800
087219418
Gaetan Vanstraelen
Turkey (Türkiye)9 sites, 9 recruiting
- Recruiting
Sakarya University School of Medicine
Adapazarı, 54100
Tuba Hacibekiroglu
- Recruiting
Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi
Ankara, 06200
Mehmet Dal
- Recruiting
Ankara University Health Practice and Research Hospitals
Ankara, 06620
00905326560206
Selami Toprak
- Recruiting
Memorial Antalya Hospital
Antalya, 07090
Fatih Demirkan
- Recruiting
Yeditepe Üniversitesi Koşuyolu Hastanesi
Istanbul, 34718
Elif Birtas Atesoglu
- Recruiting
Ege Universitesi Hastanesi
Izmir, 35100
905325566128
Güray Saydam
- Recruiting
Kocaeli Üniversitesi
İzmit, 41380
05076771924
Ozgur Mehtap
- Recruiting
VM Medical Park Mersin Hastanesi
Mersin, 33200
111111111
ANIL TOMBAK
- Recruiting
Ondokuz Mayıs Universitesi
Samsun, 55139
Mehmet Turgut
United Kingdom8 sites, 8 recruiting
- Recruiting
Heartlands Hospital
Birmingham, B9 5SS
Shankara Paneesha
- Recruiting
The Beatson West of Scotland Cancer Centre
Glasgow, G12 0YN
0141 301 7711
Mark Rafferty
- Recruiting
Northwick Park Hospital
Harrow, HA1 3UJ
02088692742
Thomas Lofaro
- Recruiting
St James's University Hospital
Leeds, LS9 7TF
01132433144
Talha Munir
- Recruiting
Lincoln County Hospital
Lincoln, LN2 5QY
07833432491
Marios Tsoutsoukis
- Recruiting
Clatterbridge Cancer Centre - Liverpool
Liverpool, L7 8YA
Stella Williams
- Recruiting
Hammersmith Hospital
London, W12 0HS
Sasha Marks
- Recruiting
Singleton Hospital
Swansea, SA2 8QA
017920285547
Unmesh Mohite
France6 sites, 6 recruiting
- Recruiting
Centre Hospitalier d'Argenteuil Victor Dupouy
Argenteuil, 95107
driss chaoui
- Recruiting
Centre Hospitalier Universitaire de Caen - Hôpital Côte de Nacre
Caen, 14033
Baptiste DELAPIERRE
- Recruiting
Centre Hospitalier du Mans
Le Mans, 72000
+33255463467
Kamel Laribi
- Recruiting
Groupe Hospitalier de la Région de Mulhouse et Sud Alsace - Hôpital Emile Muller
Mulhouse, 68100
Bernard Drenou
- Recruiting
Centre Antoine-Lacassagne
Nice, 06189
Luca INCHIAPPA
- Recruiting
Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau
Tours, 37044 Cedex 9
Caroline Dartigeas
Germany6 sites, 6 recruiting
- Recruiting
MV-Zentrum für Onkologie und Hämatologie
Cologne, 50677
Jan-Phillip Weber
- Recruiting
Centrum für Hämatologie und Onkologie Bethanien
Frankfurt, 60389
00496956005621
Christian Schmitt
- Recruiting
OSP Göttingen
Göttingen, 37073
0049551488795915
Michael Metz
- Recruiting
Onkologisches Ambulanzzentrum Hannover
Hanover, 30171
004989979680
Michael Gärtner
- Recruiting
Klinikum Aschaffenburg-Alzenau
Hösbach, 63768
0049 60214527391
Manfred Welslau
- Recruiting
InVO Institut für Versorgungsforschung in der Onkologie
Koblenz, 56068
49 261 921 5693-0
Rudolf Weide
Romania6 sites, 6 recruiting
- Recruiting
Fundeni Clinical Institute
Bucharest, 022328
40212750500
Ana Maria Moldovianu
- Recruiting
Spitalul Clinic Colțea
Bucharest, 030171
0744150652
Gabriela Borsaru
- Recruiting
Institutul Oncologic Cluj
Cluj-Napoca, 400015
400741337480
Ciprian Tomuleasa
- Recruiting
Spitalul Clinic Municipal Filantropia Craiova
Craiova, 200143
0735439439
Ocroteala Luminita
- Recruiting
Institutul Regional de Oncologie
Iași, 700483
40722565781
Catalin Danaila
- Recruiting
Ovidius Clinical Hospital OCH
Ovidiu, 905900
0724877013
Andreea Caloian
South Korea6 sites, 6 recruiting
- Recruiting
Pusan National University Hospital
Busan, 49241
+821089371258
Ho-Jin Shin
- Recruiting
Chonnam National University Hwasun Hospital
Hwasun-gun, 58128
DEOK HWAN YANG
- Recruiting
Seoul National University Hospital
Seoul, 03080
Ja Min Byun
- Recruiting
Samsung Medical Center
Seoul, 06351
Seok Jin Kim
- Recruiting
The Catholic Univ. of Korea Seoul St. Mary's Hospital
Seoul, 06591
82222586056
Ki-Seong Eom
- Recruiting
The Catholic University of Korea, Yeouido St. Mary's Hospital
Seoul, 07345
+821042324067
Youngwoo Jeon
Poland5 sites, 5 recruiting
- Recruiting
IN VIVO
Bydgoszcz, 85-048
Jaroslaw Czyz
- Recruiting
Pratia Onkologia Katowice
Katowice, 40-519
+4832 3499751
Sebastian Grosicki
- Recruiting
Pratia MCM Krakow
Krakow, 30-727
+48 602338290
Wojciech Jurczak
- Recruiting
AIDPORT Sp. z o.o.
Skórzewo, 60-185
Michal Kwiatek
- Recruiting
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu
Wroclaw, 50-367
501419272
Tomasz Wrobel
Czechia4 sites
- Active, not recruiting
Fakultní nemocnice Brno Bohunice
Brno, 625 00
- Active, not recruiting
Fakultni nemocnice Hradec Kralove
Hradec Králové, 500 05
- Completed
Fakultni nemocnice Kralovske Vinohrady
Prague, 100 34
- Active, not recruiting
Vseobecna fakultni nemocnice v Praze
Prague, 12808
Greece4 sites, 4 recruiting
- Recruiting
Evangelismos General Hospital of Athens
Athens, 106 76
+302107201721
Maria Bouzani
- Recruiting
Attikon General University Hospital
Chaïdári, 12462
0030 2105832307
Vasiliki Pappa
- Recruiting
G. Papanikolaou General Hospital
Thessaloniki, 570 10
+302313307533
Niki Stavroyianni
- Recruiting
General Hospital of Athens "Laiko"
Αthens, 11526
Theodoros Vassilakopoulos
Hungary4 sites, 4 recruiting
- Recruiting
Semmelweis Egyetem
Budapest, 1088
36208258660
ZSOLT GYORGY Nagy
- Recruiting
Dél-Pesti Centrumkórház
Budapest, 1097
+3630 455 8218
Zoltan Matrai
- Recruiting
Pécsi Tudományegyetem Klinikai Központ
Pécs, 7624
+36 72 536 000
Hussain Alizadeh
- Recruiting
Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ
Szeged, 6725
+36704391136
Szabolcs Modok
Slovakia4 sites, 4 recruiting
- Recruiting
Fakultna nemocnica s poliklinikou F.D.Roosevelta Banska Bystrica
Banská Bystrica, 975 17
+421915803313
Anna Vallova
- Recruiting
Narodny onkologicky ustav
Bratislava, 833 10
Eva Mikuskova
- Recruiting
Univerzitna Nemocnica L. Pasteura Kosice
Košice, 040 11
+421556404410
Tomas Guman
- Recruiting
Univerzitna nemocnica Martin
Martin, 036 59
421902101385
Juraj Sokol
Canada2 sites, 2 recruiting
- Recruiting
Royal Victoria Regional Health Centre
Barrie, L4M 6M2
Derek Nay
- Recruiting
Saskatoon Cancer Centre
Saskatoon, S7N4H4
Julie Stakiw
Denmark2 sites, 2 recruiting
- Recruiting
Aarhus Universitetshospital, Skejby
Aarhus, 8200
Hans Bentzen
- Recruiting
Odense Universitetshospital
Odense, 5000
Annika Rewes
About this study
Official title: A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With a Covalent Bruton Tyrosine Kinase Inhibitor
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The purpose of Part 2 of this study is to evaluate pirtobrutinib monotherapy in participants with treatment-naïve CLL/SLL with 17p deletions. Participation in Part 1 is expected to last approximately 3 years. Participation in Part 2 is expected to last up to 2 years.
- Being tested
- Pirtobrutinib
- Medical subject headings
- Leukemia, Lymphocytic, Chronic, B-Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PirtobrutinibDrug
Administered Orally.
| Study group | Role | What they receive |
|---|---|---|
| Pirtobrutinib Standard Dose (Dose 1)-Part 1 | Active comparator | Pirtobrutinib administered orally. Receives: Drug: Pirtobrutinib |
| Pirtobrutinib Dose 2-Part 1 | Experimental | Pirtobrutinib administered orally. Receives: Drug: Pirtobrutinib |
| Pirtobrutinib Dose 3-Part 1 | Experimental | Pirtobrutinib administered orally. Receives: Drug: Pirtobrutinib |
| Pirtobrutinib Standard Dose-Part 2 | Experimental | Pirtobrutinib administered orally. Receives: Drug: Pirtobrutinib |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Response Rate
Overall response rate is defined as the proportion of participants who achieve the best overall response at or before the initiation of subsequent anticancer therapy of CR, CRi, nPR, or PR. ORR will be assessed using International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 response criteria.
Measured: Baseline up to 3 years
Secondary outcomes (1)
Duration of Response
Duration of response is defined as the time from the date of the first documented CR, CRi, nPR, or PR to disease progression (per iwCLL 2018) or death from any cause.
Measured: Baseline up to 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Sep 2024
- Study start3 Jan 2025
- Primary completionJun 2028 (estimated)
- Study completionDec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Lymphocytic LeukemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 249 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Loxo Oncology, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Eli Lilly and Company
- Responsible party
- Sponsor
- Investigators
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Study director, Eli Lilly and Company
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06588478
- Sponsor's protocol ID
- 18877
- Other IDs
- 2024-515689-15-01, J2N-MC-JZNX
- Status last verified
- Nov 2026
- First submitted
- 6 Sep 2024
- Last updated
- 4 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Study at a glance
From the registry record, last updated by the sponsor on 4 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With a Covalent Bruton Tyrosine Kinase Inhibitor
- ClinicalTrials.gov ID
- NCT06588478
- Acronym / sponsor ID
- 18877
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 249 participants (estimated)
- Lead sponsor
- Loxo Oncology, Inc.Industry (pharma, biotech, devices)
- Collaborators
- Eli Lilly and Company
- Study start
- 3 Jan 2025 (actual)
- Primary completion
- Jun 2028 (estimated)
- Study completion
- Dec 2028 (estimated)
- First posted
- 19 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The purpose of Part 2 of this study is to evaluate pirtobrutinib monotherapy in participants with treatment-naïve CLL/SLL with 17p deletions. Participation in Part 1 is expected to last approximately 3 years. Participation in Part 2 is expected to last up to 2 years.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Pirtobrutinib Standard Dose (Dose 1)-Part 1 | Active comparator | Drug: PirtobrutinibPirtobrutinib administered orally. |
| Pirtobrutinib Dose 2-Part 1 | Experimental | Drug: PirtobrutinibPirtobrutinib administered orally. |
| Pirtobrutinib Dose 3-Part 1 | Experimental | Drug: PirtobrutinibPirtobrutinib administered orally. |
| Pirtobrutinib Standard Dose-Part 2 | Experimental | Drug: PirtobrutinibPirtobrutinib administered orally. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Have confirmed diagnosis of CLL/SLL as defined by iwCLL 2018 criteria.
- Part 1: Have received prior CLL/SLL treatment
- Have received at least 1, but not more than 3 lines of prior treatment for CLL/SLL
- Have received a covalent BTK inhibitor
- Part 2: Have received no prior treatment for CLL/SLL
Key exclusion criteria (9 listed)
- Have received prior treatment with a BTK degrader or a noncovalent BTK inhibitor
- Have a history of greater than or equal to (>=) Grade 3 bleeding due to treatment with a BTK inhibitor
- Have known or suspected Richter's transformation
- Have known or suspected history of central nervous system involvement by CLL/SLL
- Previous or concurrent cancer distinct from CLL/SLL within 3 years before randomization. Exceptions may occur with documented sponsor approval. Examples include:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PirtobrutinibAdministered Orally. | Drug | Pirtobrutinib Dose 2-Part 1, Pirtobrutinib Dose 3-Part 1, Pirtobrutinib Standard Dose (Dose 1)-Part 1, Pirtobrutinib Standard Dose-Part 2 |
Primary outcome
Overall Response Rate
Time frame: Baseline up to 3 years
Overall response rate is defined as the proportion of participants who achieve the best overall response at or before the initiation of subsequent anticancer therapy of CR, CRi, nPR, or PR. ORR will be assessed using International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 response criteria.
1 secondary outcome
Duration of Response
Time frame: Baseline up to 3 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Nov 2026.
- Individual participant dataSharing planned: Yes. Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Related trials for Chronic Lymphocytic Leukemia
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 2
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Not yet recruitingPhase 2
Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
RecruitingObservational study
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma
RecruitingPhase 3
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or contact
Physicians interested in becoming principal investigators please contact contact
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) study director
Eli Lilly and Company
129 sites in 18 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Pirtobrutinib in people with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, run by Loxo Oncology, Inc. at 129 sites in 18 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 129 sites in United States, Spain, Australia, Italy, Belgium and 13 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or (1-317-615-4559, LillyTrials@Lilly.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Response Rate (time frame: Baseline up to 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Nov 2026.